production, quality control and biological evaluation of 166ho-pdtmp as a possible bone palliation agent

objective(s):in this study, 166ho-1,2-propylene di-amino tetra(methy1enephosphonicacid) (166ho-pdtmp) complex  was prepared as a bone palliation agent. materials and methods:the complex was successfully prepared using an in-house synthesized edtmp ligand and 166hocl3. ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural ho(no3)3 samples  followed by radiolabeling and stability studies. biodistribution in wild type rats was also peformed. results: the complex was prepared with thespecific activity of 278 gbq/mg and high radiochemical purity (>99%, checked by itlc). 166ho-pdtmp complex was stabilized in the final preparation and in the presence of human serum (>90%) up to 72 hr. the biodistribution of 166ho-pdtmp in wild-type rats demonstrated significant bone uptake was up to 48 hr compared to 166hocl3. conclusion: the produced 166ho-pdtmp properties suggest a possible new bone palliative therapeutic to overcome the metastatic bone pains.